In the summer of 1952, American parents did something they had never done before: they kept their children away from swimming pools. From public parks. From birthday parties. The threat was invisible and merciless — a virus that struck without warning, paralyzed without pattern, and killed without regard for age, class, or geography. That year alone, more than 58,000 Americans contracted polio. Over 3,000 died. Tens of thousands survived with permanent paralysis. Many who could not breathe on their own were placed inside iron lungs — enormous metal cylinders that expanded and contracted to force air in and out of their bodies. The image of rows of children lying immobile inside these machines is one of the most haunting in modern history.

By the mid-1950s, polio was killing or paralyzing more than half a million people every year across the globe. It was not a disease of the distant past or the developing world. It was in American suburbs, British schoolyards, and the homes of presidents. Franklin D. Roosevelt — the man who led the United States through the Great Depression and World War II — had contracted the virus at the age of thirty-nine. There was no cure. There was no treatment. There was only the iron lung, the leg brace, the wheelchair — and hope.

Then came Jonas Salk.

Working at the University of Pittsburgh, Salk pursued a vaccine built from killed poliovirus — safer to produce, and simpler to test than the live-virus approaches favored by other researchers. By 1954, his vaccine was ready for what would become the largest and most complex clinical trial in medical history. Over 1.8 million children — affectionately called the "Polio Pioneers" — participated in trials across the United States, Canada, and Finland. The trial was funded largely by small donations from the American public, organized through the National Foundation for Infantile Paralysis — a grassroots effort that became known as the March of Dimes.

On April 12, 1955, Dr. Thomas Francis Jr. of the University of Michigan stepped to a podium before more than 500 scientists and physicians and made the announcement the world had been waiting for. The Salk vaccine was up to 90 percent effective against paralytic polio. Among children who received the full vaccination series, paralysis rates were a fraction of those recorded in unvaccinated children. Not a single vaccinated child died during the trials. Within minutes, news traveled by wire services and radio across the country. Church bells rang. Judges suspended court proceedings. Department stores set up loudspeakers. Parents wept in the streets.

This was an AMAZING moment because it proved, for the first time in modern medical history, that a catastrophic infectious disease could be stopped in its tracks by a single scientific tool — developed by a public institution, funded by ordinary citizens, and deployed at scale across an entire nation.

And Jonas Salk did something that set this breakthrough apart from almost every discovery that came after it. When asked at a televised interview that evening who owned the patent for the vaccine, he replied: "Well, the people, I would say. There is no patent. Could you patent the sun?" His refusal to profit personally from the discovery accelerated its worldwide distribution in ways that a patent-protected product could never have matched.

The numbers that followed are staggering. Within one year, polio deaths in the United States fell by 50 percent. By 1957, annual US cases dropped from 58,000 to just 5,600. By 1961, only 161 cases remained. In 1994, the Americas were declared entirely polio-free. Two of the three wild poliovirus strains have now been eradicated worldwide. The third — currently confined to parts of Afghanistan and Pakistan — is on the verge of becoming the second human disease in history, after smallpox, to be fully eliminated from the earth.

I want to be honest about what this story includes. The Cutter Incident of 1955 — in which one manufacturer failed to properly inactivate the virus, causing 40,000 cases of polio and killing 10 children — was a genuine tragedy that revealed critical gaps in regulatory oversight. The lesson it forced was hard-won: effective public health infrastructure does not emerge automatically. It must be built, maintained, and defended by people willing to hold both science and industry accountable.

The image that endures from April 12, 1955, is not of the iron lung or the wheelchair. It is of a young virologist standing before the world, declining to own a discovery that belonged to everyone. In 2026, as new diseases emerge and old ones resurface, and as the argument for global vaccine equity becomes more urgent with every passing year, Jonas Salk's answer to that interviewer's question is not just history. It is a standard — and a reminder that the most powerful scientific breakthroughs are the ones held in common by all of us.

We have done this before. We can do it again.

Sources: